BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23095259)

  • 1. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.
    Bayas A; Gold R; Naumann M
    J Neurol Sci; 2013 Jan; 324(1-2):53-6. PubMed ID: 23095259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic immune-mediated neuropathies: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and the Lewis-Sumner syndrome.
    Sederholm BH
    Semin Neurol; 2010 Sep; 30(4):443-56. PubMed ID: 20941678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome.
    Viala K; Renié L; Maisonobe T; Béhin A; Neil J; Léger JM; Bouche P
    Brain; 2004 Sep; 127(Pt 9):2010-7. PubMed ID: 15289267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
    Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
    Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
    Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
    J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to treatment in patients with Lewis-Sumner syndrome.
    Attarian S; Verschueren A; Franques J; Salort-Campana E; Jouve E; Pouget J
    Muscle Nerve; 2011 Aug; 44(2):179-84. PubMed ID: 21755505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin.
    Christiansen I; Markvardsen LH; Jakobsen J
    Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
    Harbo T; Andersen H; Jakobsen J
    Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients.
    Busby M; Donaghy M
    J Neurol; 2003 Jun; 250(6):714-24. PubMed ID: 12796835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lewis-Sumner syndrome in hepatitis C virus infection: a possible pathogenetic association with therapeutic problems.
    Caporale CM; Capasso M; Ragno M; Di Muzio A; Uncini A
    Muscle Nerve; 2006 Jul; 34(1):116-21. PubMed ID: 16453326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
    Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M
    J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
    Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
    J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired inflammatory demyelinating neuropathies.
    Ensrud ER; Krivickas LS
    Phys Med Rehabil Clin N Am; 2001 May; 12(2):321-34, ix. PubMed ID: 11345010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features of Lewis-Sumner Syndrome: Can Trauma Precipitate Symptoms?
    Hughes IMW; Goodridge AE
    Can J Neurol Sci; 2019 Mar; 46(2):243-247. PubMed ID: 30724154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.